This study reports the results of treatment of 18 refractory epileptic patients with sodium valproate used as an adjuvant therapy to their previously prescribed medication. Plasma levels of anticonvulsants were monitored throughout this study. Adverse clinical effects and laboratory screening results were reported. A tentative therapeutic plasma level range related to pre‐dosed blood samples of patients receiving sodium valproate is proposed. In 50%, the proportion of days when fits had occurred diminished significantly during valproate therapy especially when accompanied by significant EEG clearing.
|Number of pages||6|
|Journal||Australian and New Zealand Journal of Medicine|
|Publication status||Published - 1 Jan 1978|